8-K: Adicet Bio Initiates Enrollment for Two Phase 1 Clinical Trials Targeting Cancer and Autoimmune Diseases

Adicet Bio has announced the start of enrollment for a Phase 1 clinical trial of ADI-270 in metastatic/advanced clear cell renal cell carcinoma and the dosing of the first patient in a Phase 1 trial of ADI-001 for lupus nephritis.

Summary

• Adicet Bio has opened enrollment for a Phase 1 clinical trial of ADI-270, a gamma delta CAR T cell therapy, for patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC).
• The company plans to report preliminary clinical data from this trial in the first half of 2025.
• The first patient has been dosed in a Phase 1 clinical trial of ADI-001, a gamma delta CAR T cell therapy, for lupus nephritis.
• Adicet anticipates sharing preliminary clinical data from the ADI-001 trial in the first half of 2025.
• Enrollment for other autoimmune diseases, including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), and stiff person syndrome (SPS), is expected to begin in the first quarter of 2025.
• Enrollment for anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV) is expected to begin in the second half of 2025.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the initiation of two clinical trials and the potential of the therapies, but tempered by the inherent risks and uncertainties of clinical development.

Positives

• The initiation of two Phase 1 clinical trials demonstrates progress in Adicet's pipeline.
• ADI-270 has shown potential in preclinical data with significant tumor infiltration and resistance to the immunosuppressive tumor microenvironment.
• ADI-001 has shown robust tissue trafficking and complete CD19+ B cell depletion in preclinical studies.
• The FDA's Fast Track Designation for ADI-001 in lupus nephritis highlights the potential of the therapy.
• The company is expanding its clinical trials to include multiple autoimmune diseases.

Negatives

• The clinical trials are still in early stages, and there is no guarantee of success.
• The company is subject to risks and uncertainties that could cause actual results to differ materially from forward-looking statements.
• Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable.

Risks

• Global economic conditions and public health crises could disrupt the company's business and financial results.
• The company's ability to execute its strategy, including obtaining regulatory approvals, is not guaranteed.
• Positive results from preclinical or clinical studies may not be predictive of future results.
• Clinical studies may fail to demonstrate adequate safety and efficacy of the company's product candidates.
• The company may face challenges in meeting production and product release expectations.

Future Outlook

Adicet plans to report preliminary clinical data from the ADI-270 and ADI-001 trials in the first half of 2025 and to expand enrollment to additional autoimmune diseases in the coming quarters.

Management Comments

• Chen Schor, President and Chief Executive Officer, stated that emerging data from ADI-270 have shown potential in addressing the gap in solid tumor treatment.
• Francesco Galimi, M.D., Ph.D., Senior Vice President and Chief Medical Officer, said that dosing the first lupus nephritis patient in the ADI-001 trial marks an important step forward in improving the lives of patients affected by autoimmune diseases.

Industry Context

The announcement is significant as it highlights the growing interest in gamma delta T cell therapies for both cancer and autoimmune diseases, areas with high unmet medical needs. The company is attempting to address the limitations of current CAR T cell therapies by using allogeneic off-the-shelf gamma delta T cells.

Comparison to Industry Standards

• Adicet is competing with other companies developing CAR T-cell therapies, such as Gilead (Kite Pharma) and Novartis, which have focused primarily on hematological malignancies.
• The use of gamma delta T cells is a differentiating factor for Adicet, as most CAR T-cell therapies use alpha-beta T cells.
• The company's approach to solid tumors with ADI-270 is notable, as this area has been challenging for traditional CAR T-cell therapies.
• The expansion into autoimmune diseases with ADI-001 is also a key differentiator, as most CAR T-cell therapies are focused on cancer.

Stakeholder Impact

• Shareholders may react positively to the progress in clinical trials.
• Patients with ccRCC and autoimmune diseases may benefit from these therapies if they prove successful.
• Employees may be motivated by the company's progress and potential impact on patients.
• The company's success could lead to increased revenue and growth.

Next Steps

• Adicet will continue enrolling patients in the Phase 1 clinical trial of ADI-270 for ccRCC.
• The company will continue enrolling patients in the Phase 1 clinical trial of ADI-001 for lupus nephritis.
• Adicet plans to initiate enrollment for SLE, SSc, IIM, and SPS patients in the first quarter of 2025.
• The company plans to initiate enrollment for AAV patients in the second half of 2025.
• Adicet will report preliminary clinical data from both trials in the first half of 2025.

Key Dates

Keywords

CAR T cell therapy, gamma delta T cells, clinical trial, renal cell carcinoma, lupus nephritis, autoimmune diseases, ADI-270, ADI-001, oncology, biotechnology